Science
Sunvozertinib Moves Into the First-Line Setting for EGFR Exon 20 NSCLC – Oncogene Cancer Research
Oncogene Cancer Research

Sunvozertinib Moves Into the First-Line Setting for EGFR Exon 20 NSCLC – Oncogene Cancer Research

Oncogene Cancer Research shared on LinkedIn:

“For people with EGFR exon 20 lung cancer, chemotherapy has been the standard first-line option. These mutations are notoriously difficult to target with conventional EGFR inhibitors, leaving limited precision choices early on.

But what if we could offer a targeted therapy from the start, rather than saving it for later treatment lines?

The WU-KONG28 trial, a phase 3 international study published in The New England Journal of Medicine (NEJM Group), tested exactly that.

Researchers compared sunvozertinib to standard chemotherapy (carboplatin-pemetrexed) as first-line treatment for advanced NSCLC with EGFR exon 20 insertions. The targeted approach came out ahead:

  • Progression-free survival: 10.3 months vs 7.5 months with chemotherapy (35% lower risk of disease progression or death).
  • At 12 months, 46.1% on sunvozertinib remained progression-free, vs 26.7% on chemo.
  • Response rate: 58.9% vs 31.1% in favour of sunvozertinib.

From a patient perspective, this matters. People with EGFR exon 20 mutations may now have a precision medicine option as a starting point. The stronger side effect profile is real, but the survival and response data suggest it’s a worthwhile trade. Overall survival data were still maturing, so longer-term follow-up will be important – but these results point toward a genuine advance for this specific mutation.

This is precision oncology working: match the right drug to the right mutation, from the beginning, and improve outcomes.”

Title: First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations

Authors: Caicun Zhou, Laurent Greillier, Geoffrey Liu, Thomas John, Ligang Xing, Dariusz Kowalski, Regan M. Memmott, Ozan Yazici, Meili Sun, Catherine A. Shu, Elvire Pons-Tostivint, Yun Fan, Gonzalo Fernandez-Hinojal, Elaine Shum, Mengzhao Wang, Federica Bertolini, D. Ross Camidge, Chengzhi Zhou, Ludovic Doucet, Qunying Hong, Jian Fang, Dingzhi Huang, Bo Jin, Yan Yu, Lorenzo Antonuzzo, Denis Moro-Sibilot, Jaafar Bennouna, Gilberto de Castro Jr., Li Zheng, John V. Heymach.

Read the full article.

You might be interested in: EGFR Exon 20 and HER2-Deregulated NSCLC: The Rare Lung Cancer Subtypes Moving Into a New Therapeutic Era

Sunvozertinib Moves Into the First-Line Setting for EGFR Exon 20 NSCLC - Oncogene Cancer Research

Bo Jin Caicun Zhou cancer carboplatin-pemetrexed Catherine A. Shu Chengzhi Zhou D. Ross Camidge Dariusz Kowalski Denis Moro-Sibilot Dingzhi Huang EGFR exon 20 lung cancer EGFR inhibitors Elaine Shum Elvire Pons-Tostivint Federica Bertolini Geoffrey Liu Gilberto de Castro Jr. Gonzalo Fernández Hinojal Jaafar Bennouna Jian Fang John V. Heymach Laurent Greillier Li Zheng Ligang Xing Lorenzo Antonuzzo Ludovic Doucet Lung cancer Meili Sun Mengzhao Wang NEJM NSCLC OncoDaily Oncogene Cancer Research Oncology Ozan Yazici Qunying Hong Regan M. Memmott Sunvozertinib targeted therapy The New England Journal of Medicine. Thomas John WU-KONG28 Yan Yu Yun Fan